TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing “Psychedelics to Therapeutics”, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Year 1 Q4 (vi); Year 2 Q2 (ii); Year 2 Q2 (v) and Year 2, Q3 (iii) as…


Previous articlePT304 – Jerry B. Brown, Ph.D. – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial